Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
<br><strong>Background: </strong>Spinal muscular atrophy is an autosomal recessive neuromuscular disorder that is caused by an insufficient level of survival motor neuron (SMN) protein. Nusinersen is an antisense oligonucleotide drug that modifies pre–messenger RNA splicing of the...
Hlavní autoři: | Finkel, RS, Mercuri, E, Darras, BT, Connolly, AM, Kuntz, NL, Kirschner, J, Chiriboga, CA, Saito, K, Laurent Servais, Tizzano, E, Topaloglu, H, Tulinius, M, Montes, J, Glanzman, AG, Bishop, K, Zhong, ZJ, Gheuens, S, Bennett, CF, Schneider, E, Farwell, W, De Vivo, DC, ENDEAR Study Group |
---|---|
Médium: | Journal article |
Jazyk: | English |
Vydáno: |
Massachusetts Medical Society
2017
|
Podobné jednotky
-
Nusinersen versus sham control in later-onset spinal muscular atrophy
Autor: Mercuri, E, a další
Vydáno: (2018) -
Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps
Autor: Gidaro, T, a další
Vydáno: (2018) -
Sitting in patients with spinal muscular atrophy type 1 treated with nusinersen
Autor: Aragon-Gawinska, K, a další
Vydáno: (2019) -
Infantile spinal muscular atrophy: Therapeutic (R)evolution
Autor: Daron, A, a další
Vydáno: (2019) -
Patients’ Perceptions of Nusinersen Effects According to Their Responder Status
Autor: Lilien, C, a další
Vydáno: (2024)